EnrofloxacinCAS# 93106-60-6 |
- MLN8237 (Alisertib)
Catalog No.:BCC2166
CAS No.:1028486-01-2
- CCT137690
Catalog No.:BCC2188
CAS No.:1095382-05-0
- CYC116
Catalog No.:BCC2181
CAS No.:693228-63-6
- MLN8054
Catalog No.:BCC2170
CAS No.:869363-13-3
- TAK-901
Catalog No.:BCC2180
CAS No.:934541-31-8
- PF-03814735
Catalog No.:BCC2184
CAS No.:942487-16-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 93106-60-6 | SDF | Download SDF |
| PubChem ID | 71188 | Appearance | Powder |
| Formula | C19H22FN3O3 | M.Wt | 359.39 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | BAY-Vp2674; PD160788 | ||
| Solubility | DMSO : 10 mg/mL (27.82 mM; Need ultrasonic) H2O : 1 mg/mL (2.78 mM; ultrasonic and warming and heat to 80°C) | ||
| Chemical Name | 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid | ||
| SMILES | CCN1CCN(CC1)c2cc3N(C=C(C(O)=O)C(=O)c3cc2F)C4CC4 | ||
| Standard InChIKey | SPFYMRJSYKOXGV-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Enrofloxacin is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.In Vitro:Mycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤0.312 or 0.625 μg/mL[1].In Vivo:Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment[2]. References: | |||||
Enrofloxacin Dilution Calculator
Enrofloxacin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7825 mL | 13.9125 mL | 27.8249 mL | 55.6499 mL | 69.5623 mL |
| 5 mM | 0.5565 mL | 2.7825 mL | 5.565 mL | 11.13 mL | 13.9125 mL |
| 10 mM | 0.2782 mL | 1.3912 mL | 2.7825 mL | 5.565 mL | 6.9562 mL |
| 50 mM | 0.0556 mL | 0.2782 mL | 0.5565 mL | 1.113 mL | 1.3912 mL |
| 100 mM | 0.0278 mL | 0.1391 mL | 0.2782 mL | 0.5565 mL | 0.6956 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Enrofloxacin is a fluoroquinolone antibiotic.
- Kaempferol 3-sophoroside-7-rhamnoside
Catalog No.:BCN1306
CAS No.:93098-79-4
- 8-O-Demethyl-7-O-methyl-3,9-dihydropunctatin
Catalog No.:BCN1307
CAS No.:93078-83-2
- R 59-022
Catalog No.:BCC7279
CAS No.:93076-89-2
- Isosalvianolic Acid B
Catalog No.:BCC8330
CAS No.:930573-88-9
- Phenyl benzoate
Catalog No.:BCN8522
CAS No.:93-99-2
- Benzanilide
Catalog No.:BCC8844
CAS No.:93-98-1
- 1-Phenylbutane-1,3-dione
Catalog No.:BCN3807
CAS No.:93-91-4
- Skimmin
Catalog No.:BCN4479
CAS No.:93-39-0
- Umbelliferone
Catalog No.:BCN4477
CAS No.:93-35-6
- Acetylisoeugenol
Catalog No.:BCN7075
CAS No.:93-29-8
- N-(2-Methoxyphenyl)acetamide
Catalog No.:BCC9054
CAS No.:93-26-5
- Methyl isoeugenol
Catalog No.:BCN8462
CAS No.:93-16-3
- Ciprofloxacin hydrochloride
Catalog No.:BCC8915
CAS No.:93107-08-5
- (S,E)-Deca-2,9-diene-4,6-diyne-1,8-diol
Catalog No.:BCN1305
CAS No.:931114-98-6
- (R,E)-Deca-2-ene-4,6-diyne-1,8-diol
Catalog No.:BCN4476
CAS No.:931116-24-4
- Tacalcitol monohydrate
Catalog No.:BCC1976
CAS No.:93129-94-3
- IOX2(Glycine)
Catalog No.:BCC2229
CAS No.:931398-72-0
- PPQ-102
Catalog No.:BCC5248
CAS No.:931706-15-9
- 2-Hydroxybenzylamine
Catalog No.:BCN1803
CAS No.:932-30-9
- 5-Aminouracil
Catalog No.:BCC8737
CAS No.:932-52-5
- Cistanoside A
Catalog No.:BCN2668
CAS No.:93236-42-1
- Boc-β-iodo-Ala-OMe
Catalog No.:BCC3052
CAS No.:93267-04-0
- CDDO-EA
Catalog No.:BCC5282
CAS No.:932730-51-3
- (±)-PPCC oxalate
Catalog No.:BCC7796
CAS No.:932736-91-9
PHARMACOKINETICS OF A SINGLE DOSE OF ORAL AND SUBCUTANEOUS ENROFLOXACIN IN CARIBBEAN FLAMINGOS (PHOENICOPTERUS RUBER RUBER).[Pubmed:28363047]
J Zoo Wildl Med. 2017 Mar;48(1):72-79.
Enrofloxacin is a fluoroquinolone antimicrobial that is widely used in veterinary medicine because of its bactericidal activity and safety in a broad range of species. Caribbean flamingos, a member of the order Phoenicopteriformes, are popular in zoological collections and suffer from a variety of conditions that can result from or lead to bacterial infection. In this study, two groups of 7 adult captive Caribbean flamingos received a single dose of 15 mg/kg Enrofloxacin, administered either orally or subcutaneously. Plasma concentrations of Enrofloxacin and its metabolite, ciprofloxacin, were measured using liquid chromatography and mass spectrometry. Pharmacokinetic analysis was performed using noncompartmental methods. The pharmacokinetic parameters for both routes of administration were similar, with a mean peak plasma concentration (Cmax) of 5.25 and 5.77 mug/ml, a mean time to peak plasma concentration (Tmax) of 1.49 and 1.1 hr, a mean area under the curve (AUC) of 49.9 and 47.3 hr.mug/ml, and a mean terminal half-life (t1/2) of 5.83 and 6.46 hr for oral and subcutaneous dosing, respectively. Conversion to ciprofloxacin was minimal, with the AUC of ciprofloxacin representing <3% of the Enrofloxacin AUC for both routes of administration. Based on the results of the present study, a dose of 15 mg/kg Enrofloxacin delivered either orally or subcutaneously in the Caribbean flamingo every 24 hr is recommended for susceptible bacterial pathogens with a minimal inhibitory concentration
Ecotoxicity of veterinary enrofloxacin and ciprofloxacin antibiotics on anuran amphibian larvae.[Pubmed:28233700]
Environ Toxicol Pharmacol. 2017 Apr;51:114-123.
The ecological risks posed by two beta-diketone antibiotics (DKAs, Enrofloxacin, ENR and ciprofloxacin, CPX), characterized by their long persistence in aqueous environments and known deleterious effect on model organisms such as zebrafish were analysed using Rhinella arenarum larvae. Sublethal tests were conducted using environmentally relevant concentrations of both ENR and CPX (1-1000mugL(-1)) under standard laboratory conditions for 96h. Biological endpoints and biomarkers evaluated were body size, shape, development and growth rates, and antioxidant enzymes (glutathione-S-transferase, GST; Catalase, CAT). Risk assessment was analysed based on ration quotients (RQ). The size and shape measurements of the larvae exposed to concentrations greater than 10mugL(-1) of CPX were lower compared to controls (Dunnett post hoc p<0.05) and presented signs of emaciation. Concentrations of 1000mugL(-1)of CPX induced GST activity, in contrast with inhibited GST and CAT of larvae exposed to ENR. Risk assessments indicated that concentrations greater than or equal to10mugL(-1) of CPX and ENR are ecotoxic for development, growth, detoxifying, and oxidative stress enzymes. It is suggested that additional risk assessments may provide evidence of bioaccumulation of CPX and ENR in tissues or organs of amphibian larvae by mesocosm sediment test conditions. Finally, intestinal microbiome studies should be considered to establish the mechanisms of action of both antibiotics.
